Detection of abnormalities of PRV-1, TPO, and c-MPL genes detected by fluorescence in situ hybridization in essential thrombocythemia

Cancer Genetics and Cytogenetics

Volumn 167, Issue 1, 2006, Pages 39-42

  Puigdecanet, Eulàlia ^a,b   Espinet, Blanca ^a,c,e   Villa, Olaya ^a   Florensa, Lourdes ^b,c,e   Besses, Carles ^d,e   Serrano, Sergi ^a,b,e   Solé, Francesc ^a,c,f  

^a Departament de Patologia   (Spain)

^b Servei de Patologia   (Spain)

^c Escola de Citologia Hematològica Soledad Woessner IMAS   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e Unitat de Recerca de Neoplàsies Hematològiques Parc de Biomèdica de Barcelona ^*  (Spain)

^f Barcelona Biomedical Research Park   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; THROMBOPOIETIN;

ARTICLE; CHROMOSOME 13Q; CHROMOSOME 20Q; CHROMOSOME 8; CHROMOSOME 9; CHROMOSOME ANALYSIS; CHROMOSOME DISORDER; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR PROBE; MYELOPROLIFERATIVE LEUKEMIA VIRUS ONCOGENE; ONCOGENE; POLYCYTHEMIA RUBRA VERA 1 GENE; PRIORITY JOURNAL; THROMBOCYTHEMIA; TRISOMY;

AUTOANTIGENS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IODIDE PEROXIDASE; IRON-BINDING PROTEINS; ISOANTIGENS; MALE; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, HEMORRHAGIC;

MYELOPROLIFERATIVE LEUKEMIA VIRUS; SUID HERPESVIRUS 1;

EID: 33646473817     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.08.016     Document Type: Article

References (13)

1. Kralovics R., and Skoda R.C. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 19 (2005) 1-13
2. Temerinac S., Klippel S., Strunck E., Roder S., Lubbert M., Lange W., Azemar M., Meinhardt G., Schaefer H.E., and Pahl H.L. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95 (2000) 2569-2576
3. Liu E., Jelinek J., Pastore Y.D., Guan Y., Prchal J.F., and Prchal J.T. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 101 (2003) 3294-3301
4. Westwood N.B., Raj K., Messinezy M., and Pearson T.C. Platelet expression of Mpl is diminished in reactive thrombocytosis and in myeloproliferative disorders, but is normal in secondary erythrocytosis. Blood 94 Suppl. 1 (1999) 491
5. Kralovics R., Buser A.S., Teo S.S., Coers J., Tichelli A., van der Maas A.P., and Skoda R.C. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102 (2003) 1869-1871
6. Teofili L., Pierconti F., Di Febo A., Maggiano N., Vianelli N., Ascani S., Rossi E., Pileri S., Leone G., Larocca L.M., and De Stefano V. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 100 (2002) 714-717
7. Mesa R.A., Hanson C.A., Li C.Y., Yoon S.Y., Rajkumar S.V., Schroeder G., and Tefferi A. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. Blood 99 (2002) 4131-4137
8. Najfeld V., Fuchs S., Merando P., Lezon-Geyda K., and Fruchtman S. Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera: implications for its role in diagnosis and pathogenesis. Exp Hematol 31 (2003) 118-121
9. Murphy S., Peterson P., Iland H., and Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34 (1997) 29-39
10. Zamora L., Espinet B., Florensa L., Besses C., Salido M., and Solé F. Incidence of trisomy 8 and 9, deletion of D13S319 and D20S108 loci and BCR/ABL translocation in non-treated essential thrombocythemia patients: an analysis of bone marrow cells using interphase fluorescence in situ hybridization. Haematologica 88 (2003) 110-111
11. Bench A.J., Nacheva E.P., Champion K.M., and Green A.R. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol 11 (1998) 819-848
12. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 105 (2005) 4187-4190
13. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland D.G., and Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 106 (2005) 1207-1209